Principal Financial Group Inc. Buys 1,750 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Principal Financial Group Inc. boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 209,021 shares of the medical research company’s stock after buying an additional 1,750 shares during the period. Principal Financial Group Inc.’s holdings in IQVIA were worth $49,532,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in IQV. Capital Performance Advisors LLP purchased a new position in shares of IQVIA in the 3rd quarter worth about $27,000. Park Place Capital Corp bought a new stake in IQVIA during the 3rd quarter valued at about $28,000. Itau Unibanco Holding S.A. purchased a new position in IQVIA in the second quarter worth about $29,000. International Assets Investment Management LLC bought a new position in shares of IQVIA in the second quarter worth approximately $32,000. Finally, Avior Wealth Management LLC increased its position in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on IQV shares. BTIG Research lowered their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Truist Financial dropped their price objective on IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a research report on Thursday, December 12th. Evercore ISI decreased their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Deutsche Bank Aktiengesellschaft reduced their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, TD Cowen lowered their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $255.82.

IQVIA Stock Up 3.0 %

IQV stock opened at $197.27 on Monday. The business’s 50-day moving average price is $208.90 and its 200-day moving average price is $223.32. The stock has a market cap of $35.80 billion, a P/E ratio of 25.89, a PEG ratio of 2.05 and a beta of 1.49. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.